Table 2.
Patient Characteristics for TMA Cases versus Non-TMA Matched Controls
| Characteristic | TA-TMA Cases (N = 13) | Non-TMA Matched Controls (N = 25) | P Value |
|---|---|---|---|
| Age, yr, median (IQR) | 50 (45–53) | 50 (40–58) | .89 |
| Female sex, % (n) | 38 (5) | 48 (12) | .73 |
| Disease, % (n) | |||
| Myeloid | 62 (8) | 76 (19) | .18 |
| Lymphoid | 23 (3) | 23 (6) | |
| Nonmalignant | 15 (2) | 0 (0) | |
| Donor, % (n) | |||
| Mismatched | 54 (7) | 40 (10) | .50 |
| Regimen, % (n) | |||
| Myeloablative | 77 (10) | 80 (20) | 1.00 |
| Previous autologous HCT, % (n) | 0 (0) | 0 (0) | 1.00 |
| GVHD prophylaxis, % (n) | |||
| Tacrolimus | 62 (8) | 60 (15) | .87 |
| Cyclosporine | 38 (5) | 32 (8) | |
| Cyclophosphamide | 0 (0) | 8 (2) | |
| Sirolimus + CNI | 0 (0) | 0 (0) | |
| aGVHD onset, d, median (IQR)* | 21 (11–34) | 21 (16–31) | .71 |
| aGVHD grade, % (n)* | |||
| II | 69 (9) | 76 (19) | .85 |
| III | 8 (1) | 8 (2) | |
| IV | 23 (3) | 16 (4) | |
| aGVHD type, % (n)† | |||
| Gut | 77 (10) | 84 (21) | .67 |
| Skin | 62 (8) | 64 (16) | 1.00 |
| Liver | 23 (3) | 24 (6) | 1.00 |
| aGVHD treatment, % (n) | |||
| Systemic corticosteroid | 100 (13) | 96 (24) | |
| Second-line (steroid-refractory)‡ | 31 (4) | 16 (4) | .41 |
| TMA onset, d, median (IQR) | 37 (23–80) | N/A | N/A |
N/A indicates not applicable.
*
These are the matching variables of the study.
†
aGVHD types are not mutually exclusive.
‡
Second-line treatment included antithymocyte globulin, infliximab, alemtuzumab, or mycophenolate.